Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Mizuho Downgrades TCR2 Therapeutics to Neutral, Lowers Price Target to $1.72

Author: Benzinga Newsdesk | March 24, 2023 06:35am
Mizuho analyst Mara Goldstein downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral and lowers the price target from $20 to $1.72.

Posted In: TCRR

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist